Factor 8 SHL denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for factor 8 shl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Factor VIII (SHL) Under Step Therapy

Blue Cross Blue Shield's step-therapy (also called "fail-first") denial means their policy requires you to try and document failure on one or more preferred (typically standard half-life) Factor VIII products before the plan will authorize an extended half-life (SHL) formulation.

This denial is highly appealable for several reasons: you may have already completed the required step(s) without realizing it; your clinical history may demonstrate that step therapy would be medically inappropriate or harmful; and many states have enacted step-therapy override laws that protect patients who would face clinically significant risks from a required step.

## Federal and State Appeal Rights

• Step-therapy override: if you are in a state with a step-therapy override law, your physician may file for an exception without requiring you to fail the step therapy, based on contraindication, prior treatment history, or medical necessity. Check your state's insurance department website.
• ERISA §503: employer-plan members have full-and-fair internal review rights. Note: ERISA plans may be exempt from state step-therapy override laws — confirm your plan type.
• ACA §2719: external review rights apply if the internal appeal is denied.
• You generally have approximately four months from the denial date to request external review.
• Expedited review: available when delay poses a serious health risk.

## Concrete Appeal Timeline

1. Determine whether you have already completed the required step — prior Factor VIII product use documented in your chart may satisfy the step-therapy requirement retroactively. 2. If a step override exception applies, file it simultaneously with your internal appeal. 3. If denied internally, escalate to external review.

## Documentation to Gather

• Prior Factor VIII product history: dates of all previous Factor VIII products used, outcomes, and specific reasons for discontinuation or inadequacy — this is your primary evidence of step completion.
• Step-therapy override grounds (if applicable):
• Prior failure on the required step product (with dates and documented outcomes).
• Clinical contraindication to the required step product (prescriber documentation).
• History of adverse event on the step product.
• Clinical evidence that the step therapy would cause clinically significant harm or disease progression.
• Annualized bleed rate and severity data: chart-documented bleed history on any prior regimen.
• Pharmacokinetic rationale: if individualized PK profiling supports SHL over standard half-life, include those results.
• Prescriber step-therapy override letter: addresses each override criterion in BCBS's published step-therapy policy and your state's override law (if applicable), citing specific chart facts.

## Criteria-Mapping Structure

Obtain BCBS's current step-therapy policy for Factor VIII SHL products and map each requirement:

| Step Requirement | Evidence of Completion or Override Basis | |---|---| | Trial of [required standard half-life product] | [Product name, dates of use, documented outcome from chart] | | Documented failure or intolerance | [Clinical documentation: breakthrough bleeds, adverse event, or prescriber contraindication letter] | | Override criterion met | [Cite applicable state law or plan exception provision + clinical evidence] |

Verify the exact step-therapy requirements in BCBS's current utilization-management policy for Factor VIII and confirm all clinical standards against the FDA-approved prescribing information. Also consult your state's department of insurance for step-therapy override rights applicable to your plan type.